company background image

Novartis IndiaBSE:500672 Stock Report

Market Cap







14 Oct, 2021


Company Financials
500672 fundamental analysis
Snowflake Score
Future Growth0/6
Past Performance4/6
Financial Health4/6

500672 Overview

Novartis India Limited operates as a healthcare company in India.

Novartis India Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Novartis India
Historical stock prices
Current Share Price₹795.55
52 Week High₹538.05
52 Week Low₹1,099.00
1 Month Change-6.52%
3 Month Change-20.73%
1 Year Change25.66%
3 Year Change8.39%
5 Year Change18.07%
Change since IPO101.40%

Recent News & Updates

Shareholder Returns

500672IN PharmaceuticalsIN Market

Return vs Industry: 500672 exceeded the Indian Pharmaceuticals industry which returned 22.5% over the past year.

Return vs Market: 500672 underperformed the Indian Market which returned 64.8% over the past year.

Price Volatility

Is 500672's price volatile compared to industry and market?
500672 volatility
500672 Beta0.37
Industry Beta0.60
Market Beta1

Stable Share Price: 500672 is less volatile than 75% of Indian stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: 500672's weekly volatility (5%) has been stable over the past year.

About the Company

1947539Sanjay Murdeshwar

Novartis India Limited operates as a healthcare company in India. It offers pharmaceutical products in the areas of bone and pain, calcium portfolio, gynecology, and neurosciences, as well as generics products in the areas of gynecology, anti-TB, and anti-infectives. The company provides central nervous system products under the Tegrital and Exelon brands; pain and inflammation products under the Voveran brand; and transplantation/immunology products under the Simulect, Certican, Myfortic, and Sandimmun Neoral brands.

Novartis India Fundamentals Summary

How do Novartis India's earnings and revenue compare to its market cap?
500672 fundamental statistics
Market Cap₹19.64b
Earnings (TTM)₹227.90m
Revenue (TTM)₹3.87b


P/E Ratio


P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
500672 income statement (TTM)
Cost of Revenue₹1.51b
Gross Profit₹2.36b

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

Nov 11, 2021

Earnings per share (EPS)9.23
Gross Margin60.90%
Net Profit Margin5.89%
Debt/Equity Ratio8.8%

How did 500672 perform over the long term?

See historical performance and comparison



Current Dividend Yield


Payout Ratio


Is Novartis India undervalued compared to its fair value and its price relative to the market?


Price to Earnings (PE) ratio

Share Price vs. Fair Value

Below Fair Value: 500672 (₹795.55) is trading above our estimate of fair value (₹87.13)

Significantly Below Fair Value: 500672 is trading above our estimate of fair value.

Price To Earnings Ratio

PE vs Industry: 500672 is poor value based on its PE Ratio (86.2x) compared to the Indian Pharmaceuticals industry average (26.3x).

PE vs Market: 500672 is poor value based on its PE Ratio (86.2x) compared to the Indian market (21.9x).

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 500672's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: 500672 is good value based on its PB Ratio (2.8x) compared to the IN Pharmaceuticals industry average (3.2x).

Future Growth

How is Novartis India forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?


Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Novartis India has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Past Performance

How has Novartis India performed over the past 5 years?


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: 500672 has high quality earnings.

Growing Profit Margin: 500672's current net profit margins (5.9%) are higher than last year (3.2%).

Past Earnings Growth Analysis

Earnings Trend: 500672's earnings have declined by 40.5% per year over the past 5 years.

Accelerating Growth: 500672's earnings growth over the past year (66.6%) exceeds its 5-year average (-40.5% per year).

Earnings vs Industry: 500672 earnings growth over the past year (66.6%) exceeded the Pharmaceuticals industry 35.8%.

Return on Equity

High ROE: 500672's Return on Equity (3.2%) is considered low.

Financial Health

How is Novartis India's financial position?

Financial Position Analysis

Short Term Liabilities: 500672's short term assets (₹7.2B) exceed its short term liabilities (₹1.6B).

Long Term Liabilities: 500672's short term assets (₹7.2B) exceed its long term liabilities (₹1.3B).

Debt to Equity History and Analysis

Debt Level: 500672's debt to equity ratio (8.8%) is considered satisfactory.

Reducing Debt: 500672's debt to equity ratio has increased from 0.5% to 8.8% over the past 5 years.

Debt Coverage: 500672's operating cash flow is negative, therefore debt is not well covered.

Interest Coverage: 500672 earns more interest than it pays, so coverage of interest payments is not a concern.

Balance Sheet


What is Novartis India current dividend yield, its reliability and sustainability?


Current Dividend Yield

Dividend Yield vs Market

Notable Dividend: 500672's dividend (1.26%) is higher than the bottom 25% of dividend payers in the Indian market (0.33%).

High Dividend: 500672's dividend (1.26%) is low compared to the top 25% of dividend payers in the Indian market (1.36%).

Stability and Growth of Payments

Stable Dividend: 500672's dividends per share have been stable in the past 10 years.

Growing Dividend: 500672's dividend payments have not increased over the past 10 years.

Current Payout to Shareholders

Dividend Coverage: With its high payout ratio (108.3%), 500672's dividend payments are not well covered by earnings.

Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.

Next Steps


How experienced are the management team and are they aligned to shareholders interests?


Average management tenure


Sanjay Murdeshwar (55 yo)





Mr. Sanjay Prabhakar Murdeshwar serves as Vice Chairman and Managing Director at Novartis India Limited since June 15, 2019. Mr. Murdeshwar served as Managing Director of AstraZeneca Pharma India Limited s...

CEO Compensation Analysis

Compensation vs Market: Sanjay's total compensation ($USD95.58K) is below average for companies of similar size in the Indian market ($USD191.33K).

Compensation vs Earnings: Sanjay's compensation has been consistent with company performance over the past year.

Leadership Team

Experienced Management: 500672's management team is considered experienced (3 years average tenure).

Board Members

Experienced Board: 500672's board of directors are considered experienced (5.4 years average tenure).


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Company Information

Novartis India Limited's employee growth, exchange listings and data sources

Key Information

  • Name: Novartis India Limited
  • Ticker: 500672
  • Exchange: BSE
  • Founded: 1947
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: ₹19.643b
  • Shares outstanding: 24.69m
  • Website:

Number of Employees


  • Novartis India Limited
  • Inspire BKC, G Block
  • Part of 601 and 701
  • Mumbai
  • Maharashtra
  • 400051
  • India


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/14 15:34
End of Day Share Price2021/10/14 00:00
Annual Earnings2021/03/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.